Acute Lymphocytic Leukemia Therapeutics Market Is Increasing Due To Increasing Initiatives From Public And Private Organizations Till 2025: Grand View Research, Inc.
The
global acute lymphocytic/lymphoblastic leukemia therapeutics market is
expected to reach USD 3.4 billion by 2025, according to a new report by Grand
View Research, Inc. Increasing public and private initiatives for diagnosis of
Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and
availability of other treatment options are factors expected to increase the
adoption of ALL procedures. For instance, The Baby Friendly Initiative Program
by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach
between hospitals and healthcare institutions in Canada, aim to provide free
diagnosis and treatment services to infants suffering from ALL, who meet
certain eligibility criteria.
U.S. acute lymphoblastic leukemia therapeutics, by therapy, 2014 - 2025 (USD Million) |
Furthermore,
rising incidence of ALL is anticipated to boost the market. The disease is
prevalent among children below 5 years of age. The risk of contracting ALL is
the highest between the ages of 0 and 20. On the other hand, adults are also at
a risk of developing this condition. The median age of men diagnosed with this
condition is approximately 55 years.
Browse full
research report on Acute Lymphocytic Leukemia Therapeutics Market: www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
Further key
findings from the report suggest:
- Chemotherapy dominated the market in 2016 owing
to its high prescription rate, presence of a wide product portfolio, and
easy availability of products
- Targeted therapy is anticipated to be the most
preferred therapy in comparison to other types of therapies due to its
associated benefits such as target-specific action and its ability to
prevent collateral damage, leading to faster recovery
- Precursor B-ALL dominated the market in 2016
and is expected to be the fastest growing segment during the forecast
period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which
are its subtypes
- North America dominated the market in 2016
owing to factors such as the increase in demand for chemotherapy regimen
such as CALGB 8811 and oncaspar in this region
- Asia Pacific is anticipated to be the fastest
growing region with a lucrative CAGR during the forecast period due to
growing awareness about ALL. Furthermore, the rising disposable income and
presence of large population base are some of the factors expected to
propel the growth in this region
- Key players in this industry are Erytech
Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a.,
and Genzyme Corporation
- Key players are focusing on strategies such as
expansion of product portfolio and collaborations. For instance, in June
2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to
use Next-Generation Sequencing (NGS) technology to develop gene expression
profiles for immune-oncology therapies
Browse more
reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the global acute
Lymphocytic/Lymphoblastic leukemia therapeutics market on the basis of therapy,
type, and region:
Therapy
Outlook (Revenue, USD Million; 2014 - 2025)
- Chemotherapy
- Hyper-CVAD
- CALGB
8811 regimen
- Linker
regimen
- Nucleoside
Metabolic Inhibitors
- Oncaspar
- Targeted
therapy
- Radiation
Therapy
- Stem
cell transplantation
Type
Outlook (Revenue, USD Million; 2014 - 2025)
- Philadelphia
chromosome
- Precursor
B-cell ALL
- T-cell
ALL
Regional Outlook
(Revenue, USD Million; 2014 - 2025)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Asia
Pacific
- Japan
- China
- India
- Latin
America
- Brazil
- Mexico
- Middle
East & Africa
- South
Africa
Access
Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market
About Grand
View Research:
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
Comments
Post a Comment